PFE Pfizer Inc

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Global pharma innovator generating 65% of revenues from 12 products >$1B each; Eliquis alone = 13% of total revenues in 2025
• • Chantix returned to U.S. market in 2025 after 2021 recall; Oxbryta voluntarily withdrawn globally following negative benefit-risk assessment

Risk Factors

• • IRA Medicare Drug Price Negotiation Program: Eliquis, Ibrance, Xtandi, and Xeljanz selected for Maximum Fair Price; IRA Part D Redesign already hit 2025 revenues ~$1B
• • OBBBA (enacted July 4, 2025) cuts Medicaid/ACA funding; CBO estimates 10M more uninsured, threatening product demand and pricing

Management Discussion & Analysis

• • Revenue $62.2B in 2025, up ~$0.7B (~1%) YoY from $63.6B in 2024; international ops $25.5B (41% of total)
• • IRA Medicare Part D Redesign negatively impacted 2025 revenues by ~$1B; Eliquis alone = 13% of total revenues

Risk Factors

• • New product withdrawal risk: Voluntary withdrawal of Oxbryta in 2024 due to safety concerns, with EMA maintaining suspension and FDA review ongoing
• • Material regulatory update: IRA Medicare Part D Redesign in 2025 expected to reduce revenue by ~$1 billion, impacting pricing and manufacturer discounts

Management Discussion & Analysis

• • Revenue $16.7B Q3 2025, down 6% YoY from $17.7B, driven by $1.3B operational decline mainly due to Paxlovid (-55%) and Comirnaty (-20%)
• • Income from continuing ops before tax $3.3B Q3 2025 vs $4.7B Q3 2024; operating margin approx. 19.8% Q3 2025 vs 26.5% Q3 2024 (revenue-based approximation)

What are the latest PFE SEC filings in 2026?

Pfizer Inc (PFE) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PFE file its most recent 10-K annual report?

Pfizer Inc (PFE) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PFE 10-Q quarterly reports?

Pfizer Inc (PFE)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every PFE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PFE filed recently?

Pfizer Inc (PFE)'s most recent 8-K was filed on April 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PFE insider trading activity (Form 4)?

SignalX aggregates every PFE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PFE file with the SEC?

Pfizer Inc (PFE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PFE filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Pfizer Inc (PFE).

What is PFE's SEC CIK number?

Pfizer Inc (PFE)'s SEC CIK (Central Index Key) number is 78003. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 78003 to look up all PFE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PFE return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Pfizer Inc (PFE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.